• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗坏血酸对去铁胺诱导的特发性血色素沉着症患者尿铁排泄的影响。

Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion in idiopathic hemochromatosis.

作者信息

Conte D, Brunelli L, Ferrario L, Mandelli C, Quatrini M, Velio P, Bianchi P A

出版信息

Acta Haematol. 1984;72(2):117-20. doi: 10.1159/000206370.

DOI:10.1159/000206370
PMID:6437113
Abstract

The effect on urinary iron excretion (UIE) of vitamin C administered orally 2 h after the start of an 8-hour desferrioxamine (DF) i.v. infusion was studied in 12 patients with untreated idiopathic hemochromatosis (IH). Mean +/- SEM basal UIE of 324.6 +/- 84.6 micrograms/24 h increased after a 1-gram i.v. DF infusion to 8,778.5 +/- 1,191.4 micrograms/24 h; when vitamin C 1 or 2 g were added to DF i.v. infusion, there were further increases to 11,241.5 +/- 1,486.1 (p less than 0.01) and 13,531.2 +/- 1,697.2 micrograms/24 h (p less than 0.05 versus the last value), respectively. Basal UIE did not significantly increase after oral vitamin C administration alone. No side effects were observed.

摘要

在12例未经治疗的特发性血色素沉着症(IH)患者中,研究了在8小时静脉注射去铁胺(DF)开始2小时后口服维生素C对尿铁排泄(UIE)的影响。12例患者静脉注射1克DF后,平均±标准误的基础UIE从324.6±84.6微克/24小时增加到8,778.5±1,191.4微克/24小时;当在静脉注射DF时添加1克或2克维生素C时,UIE进一步分别增加到11,241.5±1,486.1微克/24小时(p<0.01)和13,531.2±1,697.2微克/24小时(与最后一个值相比p<0.05)。单独口服维生素C后基础UIE没有显著增加。未观察到副作用。

相似文献

1
Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion in idiopathic hemochromatosis.抗坏血酸对去铁胺诱导的特发性血色素沉着症患者尿铁排泄的影响。
Acta Haematol. 1984;72(2):117-20. doi: 10.1159/000206370.
2
The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion.
Br J Haematol. 1969 Dec;17(6):563-8. doi: 10.1111/j.1365-2141.1969.tb01407.x.
3
Ascorbic acid status in idiopathic hemochromatosis.
Digestion. 1978;17(6):479-87. doi: 10.1159/000198154.
4
[Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].[铁螯合疗法(去铁胺和抗坏血酸)在血色沉着病和库利贫血中的进一步经验]
Minerva Med. 1978 Mar 17;69(13):811-21.
5
Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults.持续静脉输注去铁胺。成人继发性血色素沉着症的治疗。
JAMA. 1978 May 19;239(20):2149-51.
6
Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.皮下注射去铁胺和口服维生素C对先天性再生障碍性贫血及与5q-综合征相关的难治性贫血中铁排泄的影响。
Am J Pediatr Hematol Oncol. 1982 Summer;4(2):115-23.
7
Four-hour measurement of urinary iron excretion after deferoxine treatment: a rapid, simple method for study of iron excretion.去铁胺治疗后4小时尿铁排泄量的测定:一种研究铁排泄的快速、简便方法。
Am J Gastroenterol. 1990 May;85(5):554-7.
8
Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
Lancet. 1977 May 7;1(8019):977-9. doi: 10.1016/s0140-6736(77)92279-6.
9
Effect of phenylhydrazine-induced haemolysis on the urinary excretion of iron after desferrioxamine.苯肼诱导溶血对去铁胺后铁尿排泄的影响。
Lancet. 1967 Jan 14;1(7481):71-4. doi: 10.1016/s0140-6736(67)92473-7.
10
[Post-desferrioxamine urinary iron in iron-overload states].[去铁胺治疗后铁过载状态下的尿铁情况]
Rev Clin Esp. 1970 Jul 31;118(2):151-8.

引用本文的文献

1
The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.天然和合成螯合剂在医学中的重要性和必要性:有效治疗铁过载和缺铁症的前景增加。
Int J Mol Sci. 2024 Apr 25;25(9):4654. doi: 10.3390/ijms25094654.
2
Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.药物选择和剂量、医学中的最佳治疗和风险/效益评估:铁螯合剂药物的范例。
Int J Mol Sci. 2023 Nov 25;24(23):16749. doi: 10.3390/ijms242316749.
3
The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases.
去铁酮在将地中海贫血从致命疾病转变为慢性疾病过程中所起的关键作用及其在非铁过载疾病中重新应用面临的挑战
Pharmaceuticals (Basel). 2023 Jul 18;16(7):1016. doi: 10.3390/ph16071016.
4
Using substantial reductant concentration with chelation therapy to enhance small aggregate dispersal, iron mobilization, and its clearance in neurodegenerative diseases.在神经退行性疾病中,使用高浓度还原剂结合螯合疗法来增强小聚集体的分散、铁的动员及其清除。
Front Neurosci. 2022 Sep 15;16:1006203. doi: 10.3389/fnins.2022.1006203. eCollection 2022.
5
Iron overload cardiomyopathy: Using the latest evidence to inform future applications.铁过载性心肌病:利用最新证据指导未来应用。
Exp Biol Med (Maywood). 2022 Apr;247(7):574-583. doi: 10.1177/15353702221076397. Epub 2022 Feb 7.
6
Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications.试图解开抗坏血酸与铁相互作用之谜:氧化还原、螯合作用及治疗意义
Medicines (Basel). 2020 Jul 30;7(8):45. doi: 10.3390/medicines7080045.
7
The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.去铁酮(L1)的历史及地中海贫血铁过载完全治疗的范例
Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020011. doi: 10.4084/MJHID.2020.011. eCollection 2020.